Fake medical claims threaten her coverage - moneywise.com
Fake medical claims threaten her coveragemoneywise.
Newswise — ST. LOUIS, Nov. 17, 2026 -- Geneoscopy, Inc., a healthcare diagnostics company advancing the next generation of tools for gastrointestinal health, including ColoSense, its noninvasive colorectal cancer screening test, today announced the resolution of all pending district court litigation with Exact Sciences Corporation.
Exact Sciences and Geneoscopy have settled the consolidated litigation in the U.S. District Court for the District of Delaware, and the court has dismissed all claims and counterclaims. The settlement is not an admission of liability or wrongdoing by either party. Settlement terms are otherwise confidential.
Geneoscopy achieved a string of victories at the Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office during the parties' dispute. In July 2025, the PTAB found all 20 challenged claims of Exact Sciences' U.S. Patent No. 11,634,781 unpatentable as obvious. In August 2025, after Geneoscopy prevailed at the PTAB, Exact Sciences withdrew its July 2024 motion for a preliminary injunction seeking to keep ColoSense off the market. In February 2026, Geneoscopy prevailed again before the PTAB, which found all 10 challenged claims of U.S. Patent No. 11,970,746 unpatentable as obvious. As a result, the Patent Office determined that every patent claim Exact Sciences asserted against Geneoscopy in litigation was invalid.
In accordance with the parties' stipulation of dismissal, the District Court has, among other things, dismissed...
Fake medical claims threaten her coveragemoneywise.